South Rampart Pharma, Inc
Pain relief innovation
South Rampart Pharma, Inc. is a clinical-stage biopharmaceutical company developing novel non-opioid analgesics targeting the limitations of current pain therapies, including organ toxicity and addiction.
Why Us
Best-in-class innovation
Learn how our platform leverages targeted pathway modeling to advance non-opioid analgesics with improved safety profiles.
Our Difference
Pioneer in pain relief
Advancing a New Class of Safer Pain Therapeutics
Science
Our non-opioid small molecules are engineered to bypass liver and kidney toxicity seen with standard analgesics.
Pain Medicine
SRP-001 is designed to eliminate the hepatotoxicity associated with acetaminophen. As a non-NSAID, it avoids kidney and gastrointestinal dose-limiting effects. As a non-opioid, it lacks abuse potential.
Pipeline
SRP-001 has completed its Phase 1 clinical trial with safety, high tolerability, and robust pharmacokinetics. We are planning the execution of the first Phase 2 randomized clinical trial.
featured
News
Stirred & Shaken: Navigating Potential Disruptions at the U.S. National Institutes of Health
Let's get in touch
